z-logo
Premium
Self and Nonself Stimulatory Molecules Induce Preferential Expansion of CD5 +  B Cells or Activated T Cells of Chagasic Patients, Respectively
Author(s) -
Valéria Dutra,
Colley,
PintoDias,
Gazzinelli,
Brener,
Max Domingues Pereira,
Coffman,
CorreaOliveira,
CarvalhoParra
Publication year - 2000
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1046/j.1365-3083.2000.00648.x
Subject(s) - cd5 , antigen , biology , antibody , microbiology and biotechnology , cd8 , cytotoxic t cell , t cell , in vitro , immunology , immune system , biochemistry
It has previously been demonstrated that Trypanosoma cruzi ‐derived antigens (TRP) and human parasite‐specific antibodies (Id) stimulate proliferation of cells from c hagasic patients. More recently, we have shown that activated T cells and CD5 +  B cells are present in elevated levels in the peripheral blood of c hagasic patients. Upon in vitro exposure to these two different types of stimulatory molecules (TRP, Id), we now show that each of these elevated populations respond differentially to TRP or Id. We found that stimulation with TRP led to preferential expansion of activated T cells, while Id preferentially stimulated CD5 +  B cells and CD8 +  T cells. Moreover, this expansion of CD5 +  B cells by Id was even more pronounced in cultures of cells from c hagasic patients with the severe, cardiac form of the disease, as compared to indeterminate patients. CD8 +  T cells comprise approximately 50% of the total T cells in cultures stimulated by Id while in TRP‐stimulated cultures their frequency is proportionally lower. Since parasite antigens and antiparasite antibodies are always present in the host during the chronic phase of the disease, they may also be involved with differential activation mechanisms of these cell populations in vivo .

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here